The European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, is taking place from the 19–23 October. Stay tuned here for the latest data straight from the experts, including Phase III trial updates, the first prospective study of treatment sequencing in mCRPC, and coverage of all the late-breaking abstracts.

ESMO 2018

19–23 October 2018 | Munich, Germany

ESMO 2018

19–23 October 2018 | Munich, Germany

The European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, is taking place from the 19–23 October. Stay tuned here for the latest data straight from the experts, including Phase III trial updates, the first prospective study of treatment sequencing in mCRPC, and coverage of all the late-breaking abstracts.

Positive results for trastuzumab biosimilar CT-P6 in HER2+ early breast cancer 2:33
Positive results for trastuzumab biosimilar CT-P6 in HER2+ early breast cancer
Justin Stebbing • 19 Oct 2018
MEK inhibitors for melanoma: new combination approved 2:02
MEK inhibitors for melanoma: new combination approved
Paolo Ascierto • 19 Oct 2018
Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide 1:52
Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide
Alison Birtle • 19 Oct 2018
Education is key to improve confidence in biosimilars 1:27
Education is key to improve confidence in biosimilars
Justin Stebbing • 19 Oct 2018
Emerging biomarkers in lung cancer 2:18
Emerging biomarkers in lung cancer
Martin Reck • 20 Oct 2018
Uro-Onc data at ESMO 2018: what to look out for 1:22
Uro-Onc data at ESMO 2018: what to look out for
Alison Birtle • 19 Oct 2018
EONS at ESMO: the importance of nursing and integrated care in oncology 1:00
EONS at ESMO: the importance of nursing and integrated care in oncology
Solange Peters • 20 Oct 2018
Highlights from WCLC 2018: NELSON, ALTA, IMpower133 & PACIFIC 3:36
Highlights from WCLC 2018: NELSON, ALTA, IMpower133 & PACIFIC
Martin Reck • 20 Oct 2018
The importance of HCPs feeling comfortable and confident with biosimilars 1:38
The importance of HCPs feeling comfortable and confident with biosimilars
Justin Stebbing • 19 Oct 2018
Localized high-risk prostate cancer: updated results from 12-year follow up of GETUG-12 1:17
Localized high-risk prostate cancer: updated results from 12-year follow up of GETUG-12
Alison Birtle • 19 Oct 2018
Securing access to optimal cancer care 3:07
Securing access to optimal cancer care
Solange Peters • 20 Oct 2018
PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer 5:04
PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer
Massimo Cristofanilli • 20 Oct 2018
SOLAR-1: alpelisib plus fulvestrant for advanced breast cancer 4:51
SOLAR-1: alpelisib plus fulvestrant for advanced breast cancer
Fabrice André • 20 Oct 2018
IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC 7:08
IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC
Peter Schmid • 20 Oct 2018
Women for Oncology (W4O) at ESMO 2:52
Women for Oncology (W4O) at ESMO
Solange Peters • 20 Oct 2018
ALTA-1L: brigatinib is superior to crizotinib in ALK+ NSCLC 2:18
ALTA-1L: brigatinib is superior to crizotinib in ALK+ NSCLC
Sanjay Popat
The content of VJOncology is intended for healthcare professionals